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Abstract. 
 
Pex19p is a protein required for the early 
stages of peroxisome biogenesis, but its precise function 
and site of action are unknown. We tested the interac-
 
tion between Pex19p and all known 
 
Pichia pastoris
 
 Pex 
proteins by the yeast two-hybrid assay. Pex19p inter-
acted with six of seven known integral peroxisomal 
membrane proteins (iPMPs), and these interactions 
were conﬁrmed by coimmunoprecipitation. The inter-
actions were not reduced upon inhibition of new pro-
tein synthesis, suggesting that they occur with preexist-
ing, and not newly synthesized, pools of iPMPs. By 
mapping the domains in six iPMPs that interact with 
Pex19p and the iPMP sequences responsible for target-
ing to the peroxisome membrane (mPTSs), we found 
the majority of these sites do not overlap. Coimmuno-
precipitation of Pex19p from fractions that contain per-
oxisomes or cytosol revealed that the interactions be-
tween predominantly cytosolic Pex19p and the iPMPs 
occur in the organelle pellet that contains peroxisomes. 
These data, taken together, suggest that Pex19p may 
have a chaperone-like role at the peroxisome mem-
brane and that it is not the receptor for targeting of
iPMPs to the peroxisome.
Key words: organelle biogenesis • protein localization 
• peroxin • chaperone • mPTS receptor
 
Introduction
 
The machinery for protein import into peroxisomes has
been characterized from many organisms (reviewed in
Hettema et al., 1999). Genetic studies in several different
yeast species identified at least 23 genes (
 
PEX
 
) that en-
code proteins (peroxins) necessary for peroxisomal pro-
tein import and biogenesis (Hettema et al., 1999; Koller et
al., 1999; Brown et al., 2000). Orthologs of many of these
proteins are known in human cells and are often defective
in patients suffering from specific human genetic diseases.
Despite this rapid growth in the identification of compo-
nents required for peroxisome protein localization, func-
tional characterization of these proteins has lagged.
The early stages of peroxisome matrix protein import
have been characterized mainly by studies of protein–pro-
tein interactions (reviewed in Hettema et al., 1999). Perox-
isome matrix proteins are synthesized in the cytosol and
usually contain one of two peroxisome-targeting signals
 
(PTSs),
 
1
 
 PTS1 or PTS2. These PTSs interact specifically
with predominantly cytosolic targeting receptor proteins.
The targeting receptors for PTS1 and PTS2 proteins are
encoded by 
 
PEX5
 
 and 
 
PEX7
 
, respectively, and defects in
these lead to impaired import of either PTS1- or PTS2-
containing proteins. Both PTS receptors interact with a
complex of proteins at the peroxisome membrane by bind-
ing to Pex13p and/or Pex14p, and this docking precedes
membrane translocation by an unknown mechanism.
Whereas all 
 
pex
 
 mutants have defects in the localization
of peroxisome matrix proteins, only a subset show defects
in the biogenesis of the peroxisome membrane (reviewed
in Hettema et al., 1999; Snyder et al., 1999b; Hettema et
al., 2000). Most 
 
pex
 
 mutants contain organelle remnants
that proliferate under peroxisome-inducing conditions,
and these remnants contain iPMPs. In contrast, a few 
 
pex
 
mutants are distinguished by the fact that they do not con-
tain the typical iPMP-containing remnants. For example,
 
yeast 
 
pex3
 
D
 
 mutants and the mammalian 
 
PEX16
 
 mutant
contain no detectable peroxisome remnants (reviewed in
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Hettema et al., 1999, 2000). Partial defects in iPMP local-
ization have been noted for 
 
Pppex17
 
D
 
 mutants (Snyder et
al., 1999b). However, no peroxin has been shown to bind
mPTS regions to directly mediate iPMP targeting to the
peroxisome. 
 
pex19
 
D
 
 mutants show a severe biogenesis de-
fect with no detectable remnants in 
 
S
 
.
 
 cerevisiae 
 
(Hettema
et al., 2000), and small vesicular remnants in 
 
P
 
.
 
 pastoris
 
(Snyder et al., 1999a). Despite these differences in pheno-
types for 
 
pex19
 
D
 
 mutants, Pex19p, a predominantly cyto-
solic protein (Götte et al., 1998; Snyder et al., 1999a), must
be important for the proper assembly of peroxisomes.
Previously, it was shown that Pex19p and Pex3p from 
 
S
 
.
 
cerevisiae
 
 and 
 
P
 
.
 
 pastoris 
 
interact (Götte et al., 1998; Sny-
der et al., 1999a), and that PpPex19p also interacted with
PpPex10p (Snyder et al., 1999a) and PpPex17p (Snyder et
al., 1999b). However, the nature, site, and relevance of
these interactions remain unclear. We have continued our
analysis of interactions among 
 
P
 
.
 
 pastoris
 
 peroxins and dis-
covered that Pex19p interacts with most of the iPMPs. An-
alyzing the sites to which Pex19p binds in the iPMPs, the
identification of mPTSs, the subcellular site of interaction,
and whether the interactions occur in the absence of new
protein synthesis, has greatly extended our knowledge of
the function of an important player in peroxisome biogen-
esis.
 
Materials and Methods
 
Molecular Biological Techniques
 
DNA procedures, yeast transformations, and cell growth was performed
by standard methods (Snyder et al., 1999a). All DNA-oligonucleotide
primers are listed in Table I.
 
Two-Hybrid Analysis
 
Cloning vectors, tester strains, and screening by two-hybrid analysis have
been described (Faber et al., 1998). All two-hybrid clones were tested for
autoactivation. Two-hybrid clones containing 
 
PEX3
 
,
 
 PEX10
 
, 
 
PEX17
 
,
 
PEX19
 
,
 
 PEX22
 
,
 
 
 
and 
 
PEX22
 
 sub-domains were described previously
(Koller et al., 1999; Snyder et al., 1999a; Snyder et al., 1999b). Two-hybrid
clones containing full-length (FL) 
 
PEX
 
 genes and subdomains were am-
plified by PCR using primers as follows: 
 
PEX2
 
(FL) with 2H2u and 2H2d;
2.1 with primers 2H2u and 2H2.6d; 2.3 with 5
 
9
 
2.3 and 2H2d; 3.1 with 5
 
9
 
3.1
and 2h3.1d; 3.2 with 5
 
9
 
3.2 and 2h3.2d; 3.3 described elsewhere (Snyder et
al., 1999a); 10.1 with 5
 
9
 
10.1 and 3
 
9
 
10.1; 10.2 with 5
 
9
 
10.2 and 2h10d; 10.3
with 5
 
9
 
10.3 and 3
 
9
 
10.1; 
 
PEX13
 
(FL) with 2h13u and 2h13d; 13.1 with 2h13u
and P13TMD; 13.2 with 5
 
9
 
13.2 and 2h13.2d; 13.3 with P13SH3u and
2H13d; 17.1 with 2h17u and 2hMPTSd; 17.2 and 17.3 described elsewhere
(Snyder et al., 1999b). All PCR products were cloned into pCRblunt (In-
vitrogen) excised with the following enzymes and ligated into compatibly
cut pKNSD55: 
 
PEX2
 
 clones with BamHI and EcoRI; 
 
PEX3
 
 with BglII
and PstI; 
 
PEX10
 
 with BamHI and EcoRI; 
 
PEX13
 
 with BglII and SpeI;
 
PEX17
 
 with BglII and EcoRI.
 
Green Fluorescent Protein Fusions
 
Green fluorescent protein (GFP) hybrids were constructed as follows:
GFP was amplified with primers 5
 
9
 
GFPNotI and 3
 
9
 
GFPHindIII. The
resulting fragment was cut with PstI and HindIII and cloned into PstI-
HindIII cut pIB2 (Sears et al., 1998). All fragments of the iPMPs were am-
plified with the indicated primers, ligated into pCRblunt, and cut with ei-
ther BamHI or BglII (depending on the site in the 5
 
9
 
 primer) and NotI
and cloned into a BamHI-NotI cut pIB2-GFP. Fragment 2.3 was amplified
with primers 5
 
9
 
2.3 and 3
 
9
 
2.3; 2.1 with 5
 
9
 
2.1 and 3
 
9
 
2.1; 3.1 with 5
 
9
 
3.1 and
3
 
9
 
3.1; 3.2 with 5
 
9
 
3.2 and 3
 
9
 
3.2; 3.3 with 5
 
9
 
3.3 and 3
 
9
 
3.2; 10.1 with 5
 
9
 
10.1 and
3
 
9
 
10.1; 10.2 with 5
 
9
 
10.2 and 3
 
9
 
10.2; 10.3 with 5
 
9
 
10.3 and 3
 
9
 
10.1; 13.2 with
5
 
9
 
13.2 and 3
 
9
 
13.1; 13.3 with 5
 
9
 
13.3 and 3
 
9
 
13.3; 17.1 with 5
 
9
 
17.1 and 3
 
9
 
17.1;
 
17.2 with 5
 
9
 
17.2 and 3
 
9
 
17.2; 22.1 with TK31 (Koller et al., 1999) and 3
 
9
 
22.1;
22.2 with TK38 and 3
 
9
 
22.2.
 
Biochemical Techniques
 
Crude cell-free extracts, SDS-PAGE, and Western blot analyses were per-
formed as described previously (Snyder et al., 1999a). Primary antibodies
were as follows: 
 
a
 
-Pex19p (1:2,000), 
 
a
 
-Pex3p (1:10,000), 
 
a
 
-Pex2p (1:
2,000), 
 
a
 
-Pex10p (1:2,000), 
 
a
 
-Pex22p (1:2,000), 
 
a
 
-GFP (1:2,000), 
 
a
 
-Scglu-
cose-6-phosphate dehydrogenase (G6PDH) (1:2,000), and rat 
 
a
 
-HA
(1:1,000). Secondary antibodies and detection methods have been de-
scribed (Snyder et al., 1999b).
The cross-linking was a standard procedure described previously
(Rieder and Emr, 1997) with minor modifications. Cross-linking was per-
formed from five A
 
600
 
 equivalents of oleate-induced cells spheroplasted as
described previously (Faber et al., 1998). For each cross-linking reaction,
spheroplasts (5 A
 
600 
 
units) were pelleted and resuspended in 1 ml lysis
buffer (20 mM potassium phosphate pH 7.5, 1 mM EDTA, and protease
inhibitors). DSP (dithiobis[succinimidyl propionate]) (Pierce Chemical
Co.) was added to a final concentration of 200 
 
m
 
g/ml and incubated for 30
min at room temperature. DSP was dissolved in DMSO just before use at
a concentration of 20 mg/ml. The cross-linker was quenched by adding
 
Table I. Primers
 
Name DNA sequence (5
 
9
 
®
 
3
 
9
 
)
 
2h2u 
 
GCGGATCCATGCCCAATAGGCTCATACC
 
2h2d
 
GATCCTGCAGCTATAACGCACCAACGAAAAAAC
 
5
 
9
 
2.1
 
AGGATCCATGCCCAATAGGCTCATACC
 
2h2.5d
 
AGAATTCCTAATCAGTCTCTAGATCATAATCTTC
 
5
 
9
 
2.5 
 
AGGATCCATGGGAGAAGACTTGAGCACC
 
2H2.6d
 
AGAATTCCTAACTTCCAGATACCAGAAATGTAAC
 
5
 
9
 
3.1
 
AAGATCTATGTTGGAGTACACGGCAGG
 
2h3.1d
 
GCGCCTGCAGCTATGGTTCACAAAGTACTGGCAGTG
 
5
 
9
 
3.2
 
AAGATCTATGATTATGGACGATTTGCCAGTAG
 
5
 
9
 
3.3
 
AAGATCTATGGTAATCCACTGTGCTTAGTGACGATTTC
 
2h3.2d
 
GCGCCTGCAGCTAAGGATCAAAATTAGAGTATAC
 
5
 
9
 
10.1
 
AGGATCCATGCCCCCATCTGAAGAGATC
 
3
 
9
 
10.2hy
 
ACTAGGTCAAAAAATAAGGCAAGATGGCG
 
5
 
9
 
10.2 
 
AGGATCCATGAGGTTATTTCGGCGATAAAATCC
 
2h10d
 
GAGAGAATTCTCAAAATACAACCAAGAAGTAC
 
5
 
9
 
10.3
 
AGGATCCGGGGAAGAATACGTTGACCTAATC
 
2h13u
 
GTCCAGATCTATGAGTGACTCATCAGCTCC
2h13d CGCGACTAGTTTATGTCTTCATCTTCTGAAATTC
P13TMD CGCGACTAGTTAAAAGATACGGAAATCCCAC
5913.2 AGGATCCATGATCAACTGGTTGAAACGAATC
P13SH3u GTCCAGATCTAAGAAATTAATTGCTCATCTTGC
2h17u GTCCAGATCTATGTCGTCAAGGCGCAACG
2hMPTSd GGAATTCCTAACGAGTCAAAAGAGCAG
17cytU GCGCAGATCTCGACCTATGTTGAAGCTTC
2H17NB GAATTCTTAAAACTTGATCGTCTGTCTTCC
393.1  AGCGGCCGCTGGTTCACAAAGTACTGGCAGTG
393.2 AGCGGCCGCAGGATCAAAATTAGAGTATACAC
3910.1 AGCGGCCGCGGTCAAAAAATAAGGCAAGATGGCG
3910.2 AGCGGCCGCAAATACAACCAAGAAGTACCCTAG
5913.1 AAGATCTATGAGTGACTCATCAGCTCC
3913.1 AGCGGCCGCAGCAATTAATTTCTTTAAAAGATACGG
5913.3  AGGATCCATGCATCTTGCTGAGACCAGTC
3913.3 AGCGGCCGCTGTCTTCATCTTCTGAAATTCTG
5917.1  AGGATCCATGTCGTCAAGGCGCAACGTG
3917.1  AGCGGCCGCAGGTCGAATCAGAAAGAGGGCC
5917.2  AAGATCTATGTTGAAGCTTCAATACGAAAG
3917.2 AGCGGCCGCGGTACTAGACCTATTTCTTTTC
TK38 GGATCCATGAAGAGTTTTATAACGTCCGAC
3922.1  AGCGGCCGCGTAAACAGAGTACCCCAGTCC
3922.2  AGCGGCCGCATTGTATATATATTGATTCACTG
59GFPNotI ACTGCAGCGGCCGCGAGTAAAGGAGAAGAAC
39GFPHindIII AAAGCTTTATTTGTATAGTTCATCCATGCCSnyder et al. Pex19p Interactions at the Peroxisomal Membrane 1173
1 M hydroxylamine to a final concentration of 20 mM. The reaction was
then adjusted to 5% TCA and incubated on ice for at least 20 min. The
TCA precipitates were washed twice with 1 ml cold acetone and dried.
For each whole cell lysate control, the TCA pellet was resuspended in 0.5
ml of urea sample buffer (6 M urea, 10% b-mercaptoethanol, 6% SDS,
125 mM Tris, pH 6.8, and 0.01% Bromophenol blue), heated to 658C for
10 min, and further diluted 1:5 in urea sample buffer before loading on the
gel. For immunoprecipitations, the TCA pellets were resuspended in 100
ml urea cracking buffer (50 mM Tris, pH 7.5, 1 mM EDTA, 1% SDS, and
6 M Urea) and heated to 658C. For minus (2) cross-linker reactions, the
TCA pellet was resuspended in 100 ml of urea cracking buffer with 10 mM
b-mercaptoethanol to cleave the cross-linker before immunoprecipitation.
This was done so that all samples would be treated with cross-linker since
the migration of many proteins in SDS-PAGE is altered by treatment with
DSP and it was desirable that the proteins in 1 and 2 cross-linker samples
have the same mobility. 1 ml of IP buffer (50 mM Tris, pH 7.5, 150 mM
NaCl, 0.1 mM EDTA, and 0.5% Tween-20) was then added to the sam-
ples and the insoluble material pelleted for 20 min in a microfuge. 1 ml of
this cleared lysate was added to a clean tube. Immunoprecipitation was
performed using crude Pex19p antisera and protein A–Sepharose or affin-
ity-purified anti-Pex19p coupled to Affi-Gel Hz beads as described by the
manufacturer (Bio Rad). The immunoprecipitates were washed two times
with urea-IP buffer (100 mM Tris, pH 7.5, 200 mM NaCl, 2 M urea, and
0.5% Tween-20) and two times with IP buffer. The beads were then resus-
pended in 90 ml of 1.113 urea sample buffer lacking b-mercaptoethanol
and heated to 378C to dissociate the antigen complexes from the antibod-
ies. 90 ml of these samples were removed from the beads and placed in a
clean tube. 10 ml b-mercaptoethanol was added and the samples were
heated to 658C before SDS-PAGE to cleave the cross-linker and allow the
resolution of individual proteins. Cycloheximide was added to cells for 45
min before the standard cross-linking procedure where indicated.
Subcellular Fractionations
Differential centrifugation was performed as described (Faber et al., 1998)
following treatment with DSP. In brief, 750 ml of oleate-grown cells
(z1,000 A600 total) where spheroplasted, washed with spheroplasting
buffer, and resuspended in 50 ml spheroplasting buffer. DSP was added to
200 mg/ml and incubated for 30 min at room temperature. Spheroplasts
were then pelleted and processed for differential centrifugation. Nyco-
denz gradient analysis of cellular fractions is described elsewhere (Faber
et al., 1998).
Results
Pex19p Interacts with Six Different iPMPs
in P. pastoris
We examined the protein interactions between Pex19p
and all P. pastoris peroxins using the yeast two-hybrid system.
Previously, we reported an interaction between Pex19p
transcriptional activation-domain fusions and DNA-bind-
ing domain fusions of Pex3p, Pex10p, and Pex17p that
leads to activation of transcription of the HIS3 reporter-
gene and a His1 phenotype for the two-hybrid tester strain
(Snyder et al., 1999a,b; Fig. 1). In this study, we confirmed
these associations and, in addition, we observed interac-
tions between Pex19p and Pex2p, Pex13p, and Pex22p
(Fig. 1). We did not observe an interaction between
Pex19p and Pex1p, Pex5p, Pex6p, Pex12p, or Pex14p. We
could not test the interaction of Pex19p with Pex4p,
Pex5p, Pex7p, and Pex8p since these proteins autoacti-
vated transcription as DNA-binding domain fusion pro-
teins. These results are significant because they demon-
strate that Pex19p interacts with six of the seven iPMPs
known in P. pastoris. The only known iPMP from P. pas-
toris that did not interact with Pex19p in the two-hybrid
assay was Pex12p. However, as described below it may in-
teract indirectly with Pex19p.
We confirmed the interactions observed in the two-hybrid
analysis by coimmunoprecipitation experiments. For this
analysis, we used strains expressing HA epitope–tagged,
fully functional versions of Pex13p (Johnson, M.A., W.B.
Snyder, M. Veenhuis, S. Subramani, and J.M. Cregg, man-
uscript submitted for publication) and Pex17p (Snyder
et al., 1999b) to facilitate the detection of the coprecipi-
tated proteins in anti-Pex19p immunoprecipitations. Pro-
tein complexes were cross-linked with DSP to allow im-
munoprecipitation under denaturing conditions. In these
Pex19p immunoprecipitations, we observed that Pex2p,
Pex3p, Pex10p, Pex13HAp, Pex17HAp, and Pex22p coim-
munoprecipitated with Pex19p in a cross-linker–depen-
dent manner (Fig. 2, lanes 1 and 2). Previously, we reported
that this technique does not cross-link all peroxisomal pro-
teins into one complex (Koller et al., 1999; Snyder et al.,
1999b) and we did not observe Pex14p, a PMP (Johnson,
M.A., W.B. Snyder, M. Veenhuis, S. Subramani, and
J.M. Cregg, manuscript submitted for publication), in the
Pex19p immunoprecipitations (Fig. 2). This indicates that
Pex19p specifically forms complexes with these six iPMPs
under physiological conditions. Since 25-fold more cell ex-
tract is shown from the immunoprecipitations than the
whole cell lysates, cross-linking between Pex19p and a
given iPMP is very inefficient, with ,1% of the total cellu-
lar pool of each iPMP found in the coimmunoprecipitates
with Pex19p. The remaining iPMP that did not show an in-
teraction with Pex19p in the two-hybrid assay, Pex12p,
also formed a complex with Pex19p (not shown), but this
interaction might be indirect since it was not observed in
the two-hybrid test (see Discussion) and was not examined
further.
Pex19p Interacts with Preexisting, and Not with Newly 
Synthesized, Pools of iPMPs
To determine whether the interactions occurred between
Pex19p and the newly synthesized iPMPs, we disrupted all
new protein synthesis and performed the coimmunopre-
cipitation assay. Treatment of P. pastoris with 1 mg/ml of
cycloheximide inhibits .90% of protein synthesis (Tuttle
and Dunn, 1995, and our unpublished data). We treated
cells with cycloheximide for 45 min and then performed
the cross-linking and coimmunoprecipitation as usual. We
did not see any difference in the quantity of coimmuno-
precipitated proteins in the presence or absence of cyclo-
heximide (Fig. 2). This suggests that complex formation
between Pex19p and the six iPMPs examined occurs in the
absence of new protein synthesis with the preexisting
pools which are at the peroxisome membrane.
Pex19p-binding Sites on the iPMPs Generally Do Not 
Overlap with mPTSs
To determine if Pex19p, a predominantly cytosolic pro-
tein, functions like a targeting receptor by binding the
mPTSs, we first needed to identify the mPTS regions in
the iPMPs. For this purpose the mPTS regions must be
sufficient to bring iPMPs to the peroxisome, but are not
necessarily required for insertion into the membrane.
GFP fusions were constructed which contained fragments
of an iPMP at the amino terminus of GFP (Fig. 1). The lo-
calization of these PMP-GFP fusion proteins was assayedThe Journal of Cell Biology, Volume 149, 2000 1174
by density gradient centrifugation and Western blotting,
to determine the positions of marker proteins and the
PMP-GFP fusions in the gradient. As shown in Fig. 3 and
summarized in Fig. 1, a region of the iPMPs that is able to
function as a mPTS was defined for all of the iPMPs (Figs.
1 and 3, constructs 2.1, 3.1, 10.3, 13.2, 17.1, and 22.1). For
Pex2p, Pex3p, Pex17p, and Pex22p the remaining portions
of the proteins did not contain targeting information, at
least in the context of the GFP fusions we created, thereby
demonstrating the necessity of the mPTS. For Pex10p
the remaining regions, 10.1 and 10.2, were not expressed,
or were unstable in yeast. For Pex13p only the large cy-
tosolic, SH3 containing, domain (13.3) was additionally
tested and did not function as a mPTS. These data re-
vealed the mPTS regions of the examined iPMPs and sug-
gest that the proteins probably do not contain multiple
mPTSs.
The hypothesis that Pex19p is the cytosolic receptor for
the targeting of iPMPs to the peroxisome was further
tested by determining whether the site of Pex19p binding
in the iPMPs coincided with the mPTSs. Fig. 1 summarizes
the data of the two-hybrid analysis between Pex19p and
the various sub-domains of the iPMPs examined. We nar-
rowed the subdomain of Pex19p interaction for all of the
iPMPs except Pex17p. For Pex3p, Pex10p, Pex13p, and
Pex22p the interaction domain did not function as a
mPTS. Several sub-domains of the 17.3 region were tested
but did not interact (not shown). It is unclear where
Pex19p binds in Pex17p, but Pex19p did not show an inter-
action with the mPTS (17.1). Only for Pex2p did we ob-
serve Pex19p interacting with segments containing the
mPTS (2.1). This clearly demonstrates that the Pex19p-
binding sites are distinct from the mPTS regions in at least
four of the six iPMPs examined.
Site of Interaction of Pex19p with iPMPs
Identification of the subcellular site of interaction between
Pex19p and the iPMPs is critical for understanding Pex19p
Figure 1. Summary of Pex19p interactions
and localization of PMP-GFP fusions. Rela-
tive positions of iPMP domains tested for
two-hybrid interaction with Pex19p and
mPTS function are shown. Black bars indicate
regions that functioned as a mPTS. Hatched
bars indicate regions binding to Pex19p. Note
that the mPTSs and Pex19p-binding sites are
clearly nonoverlapping for Pex3p, Pex13p,
and Pex22p. The symbol 1 indicates growth
of the strain on media lacking histidine. AA
indicates autoactivation and growth on media
lacking histidine in the absence of a Pex19p
activation domain fusion. Data for PMP-GFP
localization are in Fig. 3. Cyt indicates that
the PMP-GFP fusion was at the top of the
gradient and did not colocalize with peroxi-
somes. Per indicates that the PMP-GFP fu-
sion showed significant colocalization with
the peroxisome peak. The approximate posi-
tions of transmembrane domains from pub-
lished reports are shown by the dark boxes.
The light boxes represent putative transmem-
brane regions predicted from computer pro-
grams. NS indicates that the fusion was not
stable or not synthesized.
Figure 2. Coimmunoprecipi-
tation of six iPMPs with
Pex19p. Pex19p was immu-
noprecipitated from oleate-
grown cells expressing
Pex17HAp (S17HA) or
Pex13HAp (S13HA). Cells
treated with cycloheximide
for 45 min, where indicated,
before spheroplasting. Whole
cell lysates (w.c.) were
loaded as a control (0.02 A600
equivalent). The amount of
immunoprecipitation loaded
was 25-fold higher than that
in the lane marked w.c. (0.5
A600 equivalent). Samples
were immunoblotted to re-
veal the iPMPs. An asterisk
indicates the IgG heavy
chain. XL indicates the sam-
ples were cross-linked during
immunoprecipitation.Snyder et al. Pex19p Interactions at the Peroxisomal Membrane 1175
function. This subcellular interaction site was determined
by a cross-linking and subcellular fractionation experi-
ment. Spheroplasted cells were incubated with DSP before
the separation of subcellular fractions by differential cen-
trifugation. The fractionation yielded equivalent pro-
portions of the supernatant (S) and pellet (P) fractions
from a 27,000-g centrifugation of the homogenate (H)
fraction. The majority of iPMPs such as Pex3p, Pex10p,
Pex17HAp, and Pex22p were in the pellet fraction (Fig. 4
A). We did observe a minor amount of iPMPs in the su-
pernatant fractions and we believe that these proteins are
released from the peroxisomes during the fractionation
procedure (see below). These experiments show that cyto-
solic proteins were found in the supernatant fractions (not
shown) as was the majority of Pex19p (Fig. 4 A). Immuno-
precipitates of these fractions with anti-Pex19p contained
.95% of the cross-linked Pex3p, Pex10p, Pex17HAp, and
Pex22p in the pellet fractions (Fig. 4 B). It is important to
note that these interactions occur with the small, peroxi-
some-associated pool of Pex19p, and not with the larger,
cytosolic pool. This suggests that the peroxisome, and not
the cytosol, is the steady state site of interaction between
Pex19p and the iPMPs examined.
We suspected that the soluble iPMPs found in the frac-
tionation procedure were the result of peroxisome rupture
and not the newly synthesized pool. These procedures do
result in significant breakage of peroxisomes resulting in
the inability to pellet all peroxisomal proteins as described
previously for P. pastoris (Snyder et al., 1999a, and refer-
ences therein) and as reported recently in S. cerevisiae
(Hettema et al., 2000). To differentiate between soluble
iPMPs that result from organelle rupture and the newly
synthesized pool of iPMPs that would also be soluble, we
depleted the newly synthesized pools by treating the cells
with cycloheximide before the fractionation. As shown in
Fig. 4 C, we did not see a difference between the amount
of soluble Pex3p (S27 and S100) in cells treated with cyclo-
heximide for 45 min as compared with untreated cells.
This result leads us to believe that the minor amounts of
iPMPs in the supernatant fractions represent proteins re-
leased from the organelle and not the newly synthesized
proteins.
Discussion
Pex19p Interacts with Preexisting Peroxisomal Pools of 
Many Different iPMPs
We have shown, using the yeast two-hybrid system, that
Pex19p interacts with 6 (Pex2p, Pex3p, Pex10p, Pex13p,
Pex17p, and Pex22p) of seven iPMPs in P. pastoris. We did
not observe an interaction between Pex19p and Pex12p,
except in coimmunoprecipitation experiments. It is likely
that the observed interactions in the two-hybrid system
are direct because the test is performed in S. cerevisiae us-
ing  P. pastoris proteins. Although we can not rule out
bridging by an endogenous protein that binds to both the
DNA-binding domain fusion proteins and the transcrip-
tional activation-domain fusions in our heterologous sys-
tem, such bridging was not observed in the same test pair-
ings of P. pastoris proteins (Snyder et al., 1999b) as it was
in S. cerevisiae (Huhse et al., 1998). Furthermore, such
bridging between the endogenous S. cerevisiae proteins
and the P. pastoris two-hybrid fusion proteins seems un-
likely, since S. cerevisiae peroxins fail to complement the
corresponding P. pastoris deletion mutants (Koller et al.,
1999; Snyder et al., 1999b).
The two-hybrid interactions observed were confirmed
by coimmunoprecipitation and occurred in the absence of
new protein synthesis. Using a standard cross-linking pro-
cedure we observed Pex2p, Pex3p, Pex10p, Pex13HAp,
Pex17HAp, and Pex22p in Pex19p immunoprecipitations.
This procedure does not cross-link all peroxisomal pro-
teins (Koller et al., 1999; Snyder et al., 1999b). In fact, we
can only cross-link a very small percentage (,1%) of iPMPs
Figure 3. Analysis of mPTS function. Domains of iPMPs (see
Fig. 1) were tested for mPTS function by colocalization of PMP-
GFP (GFP) with either Pex22p (peroxisome) or G6PDH (cyto-
sol) in the Nycodenz gradient.
Figure 4. Coimmunoprecipi-
tation of iPMPs from subcel-
lular fractions with Pex19p.
Homogenate (H), superna-
tant (S), and pellet (P) frac-
tions were created as de-
scribed in Materials and
Methods. Whole fractions
(A) or anti-Pex19p immuno-
precipitates (B) were re-
solved by SDS-PAGE and
immunoblotted. A and B do
not show equivalent amounts
or exposures. As asterisk in-
dicates the IgG heavy chain.
(C) Sequential, differential
fractionation of oleate-
grown, wild-type cells incu-
bated in the presence (1) or absence (2) of cycloheximide for 45
min before lysis. PNS (post nuclear supernatant), S27 (27,000-g
supernatant), P27 (27,000-g pellet), S100 (100,000-g supernatant),
and P100 (100,000-g pellet).The Journal of Cell Biology, Volume 149, 2000 1176
to Pex19p (Fig. 2) and a control protein, Pex14p, was not
complexed to Pex19p (Fig. 2).
The prevailing model of peroxisome biogenesis posits
that iPMPs are synthesized in the cytosol and targeted
directly to the peroxisome (Lazarow and Fujiki, 1985).
Working within this model, we would predict that if
Pex19p bound to the newly synthesized pool of iPMPs ei-
ther as a chaperone, a targeting receptor, or membrane in-
sertion factor, we should have observed a decrease in the
amount of iPMPs that cross-linked to Pex19p. The coim-
munoprecipitation of the iPMPs with Pex19p was not dis-
rupted or reduced by pretreatment of the cells with cyclo-
heximide, a treatment known to disrupt new protein
synthesis (Tuttle and Dunn, 1995). This strongly suggests
that Pex19p does not form complexes with the newly syn-
thesized iPMPs, and points to the peroxisome as the site of
interaction because that is where the preexisting iPMPs
are located.
Multiple Lines of Evidence Show that Pex19p Is 
Unlikely to Function as the mPTS Receptor
The mPTSs and Pex19p-binding Sites Are Distinct in Multi-
ple iPMPs. A very attractive model for Pex19p function is
one in which Pex19p binds to multiple iPMPs at the mPTS
and consequently brings them from the cytosol to the per-
oxisome. However, our analysis of the Pex19p-binding
sites on the iPMPs and our identification of the regions
that are responsible for targeting them to the peroxisome,
the mPTSs, suggests that Pex19p is not the cytosolic recep-
tor for the mPTS. We have shown for Pex3p, Pex13p, and
Pex22p that a Pex19-binding site is separate from the
mPTS regions in these iPMPs. These data show that the
mPTSs and Pex19p-binding domains are clearly distinct in
three of the iPMPs tested.
Experimental limitations with the other iPMPs tested
pose a few potential caveats. Pex2p interacts with Pex19p
in a domain that also functions as a mPTS. However, our
analysis can not currently differentiate between the amino
acids responsible for Pex19p binding and those which are
critical solely for mPTS function in Pex2p. In a second
case, we were unfortunately unable to find a distinct
Pex19p interaction domain in Pex17p, but two-hybrid ex-
periments with S. cerevisiae proteins show that ScPex19p
binds to amino acids 52–88 of ScPex17 (W.H. Kunau,
unpublished results), which is separate from the corre-
sponding region in PpPex17p that functions as a mPTS.
Unfortunately, we were also unable to test if the Pex19p
interaction domain in Pex10p functions as a mPTS due to
the instability of the GFP fusion protein. None of these ca-
veats, however, necessarily support the hypothesis that
Pex19p is indeed the mPTS receptor in light of the addi-
tional evidence presented in this paper. Our conclusions
are therefore based on correlative evidence, that in the
majority of the iPMPs tested (Pex3p, Pex13p, Pex17p, and
Pex22p), the available data show that the mPTS and
Pex19p-binding sites are indeed nonoverlapping.
The Peroxisomal Interaction of Pex19p with Preexisting
iPMPs Is Inconsistent with a Role for Pex19p as the Cyto-
solic mPTS Receptor. Analyzing the subcellular site of Pex19p
and iPMP interactions further defined their significance.
Treatment of cells with cross-linker before lysis did not al-
ter the fractionation pattern of the proteins examined
when compared with previous reports. The fact that the
majority of Pex19p is in the supernatant fraction (Fig. 4 A,
lane S), whereas the iPMPs are found in the organelle pel-
let (Fig. 4 A, lane P), may seem paradoxical with the fact
that the proteins interact. Indeed, immunofluorescence
microscopy has also revealed that the majority of Pex19p
is cytosolic (not shown) and is not simply released from
the organelle during fractionation procedures. In the anti-
Pex19p immunoprecipitations, iPMPs were in the pellet
fractions (Fig. 4 B, lane P), with very little (few percent of
total) in the supernatant fractions (Fig. 4 B, lane S). Al-
though most of the Pex19p was cytosolic, only the Pex19p
in the organelle pellet was significantly complexed with
iPMPs. The minor amounts of iPMPs that are in the super-
natant fractions are likely to be the result of peroxisome
rupture, an often observed problem with these fractionation
procedures (Snyder et al., 1999a, and references therein;
Hettema et al., 2000). This minor pool of iPMPs that might
be released from the membrane could also be complexed
with Pex19p, thus resulting in a very low percentage of
iPMPs in the supernatant of the Pex19p immunoprecipita-
tions. Indeed, our control experiments suggested that the
nonpelletable pool of Pex3p does not represent the newly
synthesized pool since treatment with cycloheximide did
not diminish cytosolic Pex3p in fractionation experiments
(Fig. 4 C). Taken together, our results point to the fact that
the organelle-associated pool of Pex19p interacts with the
iPMPs at the peroxisome. This conclusion explains the ap-
parent paradox stated above regarding the Pex19p–iPMP
interactions. We must point out that if Pex19p initially
bound to iPMPs in the cytosol and then rapidly targeted to
the peroxisome membrane, we might miss this cytosolic
interaction in our steady state analysis. This seems un-
likely because the cytosolic iPMPs would represent the
newly synthesized pool that has not yet been targeted to
the peroxisome, but our experiment with cycloheximide
treatment does not reveal a reduction in the Pex19p–iPMP
interactions (Fig. 2). Therefore, our conclusion that the in-
teractions occur at the peroxisome membrane is supported
by multiple pieces of evidence (Figs. 2 and 4).
The Peroxisomal Interaction of Pex19p with iPMPs Is
Consistent with the Topology of Most iPMPs. Pex19p may
interact on the cytosolic side of the peroxisome membrane
as evidenced by the fact that the domains of Pex2p,
Pex13p, and Pex22p that interact with Pex19p are known
or predicted to be cytosolic. There are problems with in-
corporating the published topology of Pex10p into the
Pex19p interaction model as previously described (Snyder
et al., 1999a). For Pex3p and Pex17p, the tested domains
that interact with Pex19p span the membrane and the pre-
cise interaction domain still needs to be identified. None-
theless, the identification of cytosolic Pex19p-binding sites
on the three of the iPMPs further supports our conclusion
based on evidence from the cycloheximide treatments and
fractionation data that the interactions occur at the cytoso-
lic face of the peroxisome membrane.
Models for Pex19p Action
All the data presented clearly rule out the attractive model
in which the interactions between Pex19p and the iPMPsSnyder et al. Pex19p Interactions at the Peroxisomal Membrane 1177
mediate targeting of newly synthesized iPMPs from the cy-
tosol to the peroxisome, i.e., the mPTS-receptor model.
This model makes several predictions. First, Pex19p would
be expected to interact with the iPMPs in the cytosol, but
we show that the interactions occur at the peroxisome.
However, this analysis might not detect cytosolic interac-
tions if the iPMP–Pex19p complexes are recruited rapidly
to the membrane, but the evidence outlined in the other
points below suggests that this is not the case. Second, as
the newly synthesized pools of iPMPs are depleted during
cycloheximide treatment, cross-linking between Pex19p
and the iPMPs should diminish, but the cross-linking re-
mains the same. Third, Pex19p should bind to the mPTS
domain, but most of the Pex19p-binding domains on the
iPMPs do not function as a mPTS. Finally, pex19D mutants
should accumulate iPMPs in the cytosol, but Pex3p (Sny-
der et al., 1999a), Pex17p, and Pex22p (our unpublished
results) localized to membranous remnants. In S. cerevisiae
no iPMP-containing remnants were observed in pex19D
mutants (Hettema et al., 2000), but this could be the result
of defects in peroxisome biogenesis, not iPMP targeting,
or the inability to detect the remnants. For the proteins ex-
amined here, Pex19p does not seem to function as a mPTS
receptor, but we can not rule out that possibility for other
iPMPs.
While this manuscript was being revised, work was pub-
lished showing that in human cells multiple iPMPs interact
with Pex19p (Sacksteder et al., 2000). Our work comple-
ments that of Sacksteder et al. (2000) and reaffirms the
evolutionary conservation of the interaction of Pex19p with
multiple iPMPs. In the human system, Sacksteder et al.
(2000) conclude that Pex19p interacts with the newly syn-
thesized pool of iPMPs by binding to domains that contain
the mPTS. Several models for Pex19p function were sug-
gested, but the data could not distinguish between them.
The favored hypothesis was that Pex19p functions as the
cytosolic receptor mediating the localization of iPMPs or
as a chaperone in the cytosol for newly synthesized iPMPs.
Our data do not support these two hypotheses. In fact, when
we began this study our working model was that Pex19p
might be the mPTS receptor, but our findings based on
multiple, complementary experiments (see above) have
led us away from this idea.
Our data point to a role for Pex19p interacting with the
preexisting iPMPs at the peroxisome membrane. None of
the data are inconsistent with this conclusion, despite a
few potential caveats described above. The pex19D mutants
contain small, vesicular remnants suggesting that Pex19p
functions at an early step in peroxisome biogenesis (Sny-
der et al., 1999a). The interaction of Pex19p with multiple
iPMPs somehow allows maturation of the small vesicles to
mature peroxisomes. For iPMPs to function properly they
may need to assemble and disassemble dynamically into
multiple, heteroligomeric complexes that carry out essen-
tial functions. Evidence for iPMPs forming mutually exclu-
sive complexes with either Pex19p or the PTS receptors
has been provided (Snyder et al., 1999b). It is unlikely that
Pex19p is required for the targeting or insertion of iPMPs
into the peroxisomal membrane since it interacts mainly
with iPMPs at the peroxisome, and because it does not in-
teract with the newly synthesized iPMPs, at least three of
which are sorted to the membranes of remnants in a
Pex19p-independent manner. Rather, we envision that
Pex19p functions as an assembly or disassembly factor, or
as a chaperone, to regulate the complexes comprising the
iPMPs already in the peroxisomal membrane. Exactly how
Pex19p does this remains a subject for future work.
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